Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type kras unresectable metastatic colorectal cancer

Journal of Oncology Practice

Volumn 12, Issue 6, 2016, Pages e710-e723

  Riesco Martínez, Maria Carmen ^b   Berry, Scott R ^b   Ko, Yoo Joung ^b   Mittmann, Nicole ^b   Giotis, Angie ^b   Lien, Kelly ^b   Wong, William W L ^b   Chan, Kelvin K W ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; PROTEIN P21;

ARTICLE; CANADIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; FEBRILE NEUTROPENIA; HEALTH CARE; HUMAN; MEDICAL ONCOLOGIST; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; ONCOGENE K RAS; OVERALL SURVIVAL; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PROGRESSION FREE SURVIVAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSORY NEUROPATHY; SKIN TOXICITY; THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84974633290     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.008730     Document Type: Article

References (43)

1. International Agency for Research on Cancer: The GLOBOCAN project. http://globocan.iarc.fr/Default.aspx
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355:1041-1047, 2000
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer:Results of the TREE Study. J Clin Oncol 26:3523-3529, 2008
5. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
6. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
7. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
8. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
9. Van Cutsem E, Nordlinger B, Cervantes A: Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21:v93-v97, 2010, (suppl 5)
10. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version I. www.nccn.org/professionals/physician-gls/f-guidelines.asp
11. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
12. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
13. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008
14. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
15. Grothey A: EGFR antibodies in colorectal cancer: Where do they belong? J Clin Oncol 28:4668-4670, 2010
16. Hess GP, Wang PF, Quach D, et al: Systemic therapy for metastatic colorectal cancer: Patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 6:301-307, 2010
17. Venook A, Niedzwiecki D, Lenz HJ, et al: CALGB/SWOG 80405. Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients with KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum. J Clin Oncol 32, 2014 (suppl; abstr LBA3)
18. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
19. Bekaii-Saab TS: Recent progress in colorectal cancer: Is it worth the cost? Oncol Times 26:4-7, 2005
20. Pickard AS,Wilke CT, Lin HW, et al: Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25:365-384, 2007
21. Ministry of Health and Long-Term Care: Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob-mn.html
22. Ontario Case Cost Initiative. https://hsimi.on.ca/hdbportal/
23. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatino (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240-2247, 2014
24. Stintzing S, Jung A, Rossius L, et al: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr LBA17)
25. Lawrence D, Maschio M, Leahy KJ et al. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the firstline treatment of KRAS wild-type metastatic colorectal cancer (mCRC). J Med Econ 16:1387-1398, 2013
26. Hurwitz HI, Yi J, Ince W, et al: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14:22-28, 2009
27. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
28. Pharmacy Odette Cancer Centre
29. Sneeuw KC, Sprangers MA, Aaronson NK: The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55:1130-1143, 2002
30. Blagden SP, Charman SC., Sharples LD, et al: Performance status score: Do patients and their oncologists agree? Br J Cancer 89:1022-1027, 2003
31. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
32. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
33. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
34. Shitara K, Yokota T, Takahari D, et al: Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. Invest New Drugs 29:688-693, 2011
35. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
36. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007
37. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
38. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
39. Graham CN, Hechmati G, Hjelmgren J, et al: Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 50:2791-2801, 2014
40. Lenz H, Niedzwiecki D, Innocenti F, et al: CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum. Presented at the Annual Conference of the European Society of Medical Oncology, Madrid, Spain, September 26-30, 2014 (abstr 5010)
41. Guerriere DN, Zagorski B, Fassbender K, et al: Cost variations in ambulatory and home-based palliative care. Palliat Med 24:523-532, 2010
42. Lathia N, Mittmann N, DeAngelis C, et al: Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742-748, 2010
43. Schrag D, Dueck AC, Naughton MJ, et al: Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. J Clin Oncol 33, 2015 (suppl; abstr 6504)